Literature DB >> 33111255

Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study.

Fernando Henao1, Aranzazu Manzano2, Rafael Lopez Lopez3, Ana Luisa Gobartt4, Ramón de Las Peñas5.   

Abstract

INTRODUCTION: The ALGA study explored adherence of Spanish treatment centers to the Sociedad Española de Oncología Médica (SEOM) treatment algorithm for oncology patients with hyponatremia that requires treatment as the main cause of hospitalization, and evaluated the impact of adherence to this algorithm on patient outcomes.
METHODS: This retrospective study recruited patients aged at least 18 years with cancer, treated for at least one episode of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The primary outcome was the proportion of patients whose treatment adhered to the SEOM algorithm, evaluated using a pre-defined decision tree. Secondary outcomes included length of hospitalization, and time to serum sodium level improvement. Perceived center adherence to the SEOM algorithm was also assessed.
RESULTS: Seventy patients from four treatment centers were included. Twenty (28.6%; 95% confidence interval [CI] 18.0, 39.2) patients on hyponatremia treatment adhered to the SEOM algorithm, with a perceived adherence of 51.0-75.0%. Algorithm adherence in candidates for chemotherapy was 36.4% (n = 8) versus 25.0% (n = 12) for non-candidates for chemotherapy. Median time to serum sodium level improvement in patients managed adherently was 80.5 h (95% CI 38.3, 331.4) versus 134.6 h (33.2, 444.9) in patients managed non-adherently. Median time to hospital discharge was 16.5 days (95% CI 8.0, 27.0) in patients managed adherently versus 9.5 days (7.0, 22.0) in patients managed non-adherently.
CONCLUSION: In Spanish centers, the SEOM algorithm was adhered to in less than one-third of patients, in contrast to higher levels of perceived adherence. This requires further investigation; however, algorithm use could require further clarification, especially in non-candidates for chemotherapy.

Entities:  

Keywords:  Cancer; Chemotherapy; Hyponatremia; Oncology; Supportive care; Tolvaptan; Treatment algorithm

Mesh:

Year:  2020        PMID: 33111255     DOI: 10.1007/s12325-020-01532-6

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  20 in total

Review 1.  Hyponatremia.

Authors:  H J Adrogué; N E Madias
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

2.  Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes.

Authors:  Simit M Doshi; Pankaj Shah; Xiudong Lei; Amit Lahoti; Abdulla K Salahudeen
Journal:  Am J Kidney Dis       Date:  2011-10-15       Impact factor: 8.860

3.  Clinical practice guideline on diagnosis and treatment of hyponatraemia.

Authors:  Goce Spasovski; Raymond Vanholder; Bruno Allolio; Djillali Annane; Steve Ball; Daniel Bichet; Guy Decaux; Wiebke Fenske; Ewout J Hoorn; Carole Ichai; Michael Joannidis; Alain Soupart; Robert Zietse; Maria Haller; Sabine van der Veer; Wim Van Biesen; Evi Nagler
Journal:  Eur J Endocrinol       Date:  2014-02-25       Impact factor: 6.664

Review 4.  The syndrome of inappropriate antidiuresis (SIAD).

Authors:  Martin Cuesta; C J Thompson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-02-27       Impact factor: 4.690

Review 5.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Jorge J Castillo; Marc Vincent; Eric Justice
Journal:  Oncologist       Date:  2012-05-22

6.  The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period.

Authors:  Olfred Hansen; Peter Sørensen; Karin Holmskov Hansen
Journal:  Lung Cancer       Date:  2009-06-16       Impact factor: 5.705

Review 7.  Hyponatremia in cancer patients: Time for a new approach.

Authors:  Rossana Berardi; Silvia Rinaldi; Miriam Caramanti; Christian Grohè; Matteo Santoni; Francesca Morgese; Mariangela Torniai; Agnese Savini; Ilaria Fiordoliva; Stefano Cascinu
Journal:  Crit Rev Oncol Hematol       Date:  2016-03-10       Impact factor: 6.312

8.  Malignancy associated SIADH: Characterization and clinical implications.

Authors:  H Goldvaser; B Rozen-Zvi; R Yerushalmi; A Gafter-Gvili; M Lahav; D Shepshelovich
Journal:  Acta Oncol       Date:  2016-05-04       Impact factor: 4.089

9.  The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.

Authors:  Fabio A B Schutz; Wanling Xie; Frede Donskov; Monica Sircar; David F McDermott; Brian I Rini; Neeraj Agarwal; Sumanta Kumar Pal; Sandy Srinivas; Christian Kollmannsberger; Scott A North; Lori A Wood; Ulka Vaishampayan; Min-Han Tan; Mary J Mackenzie; Jae Lyun Lee; Sun-Young Rha; Takeshi Yuasa; Daniel Y C Heng; Toni K Choueiri
Journal:  Eur Urol       Date:  2013-10-26       Impact factor: 20.096

10.  Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.

Authors:  Daniele Santini; Raffaele Ratta; Francesco Pantano; Delia De Lisi; Marco Maruzzo; Luca Galli; Elisa Biasco; Azzurra Farnesi; Sebastiano Buti; Cora Nanette Sternberg; Linda Cerbone; Giuseppe Di Lorenzo; Silvia Spoto; Michelle Sterpi; Ugo De Giorgi; Rossana Berardi; Mariangela Torniai; Andrea Camerini; Francesco Massari; Giuseppe Procopio; Giuseppe Tonini
Journal:  Oncotarget       Date:  2017-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.